30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

Wendall Wierenga

Track

Insider profile

Currently holds positions in Concert Pharmaceuticals Inc, Santarus Inc, Crinetics Pharmaceuticals Inc, Onyx Pharmaceuticals Inc, XenoPort Inc and Cytokinetics Inc

Performance

Overall performance
3.4
Performance over holding periods
3.4
30 days 90 days 120 days
Average return 7% 8.2% 15.1%
Success rate 89% 68% 82%
Transactions
8 12% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Concert Pharmaceuticals Inc March 13, 2014 -
Executive Vice President - Research and Development Santarus Inc June 20, 2011 -
Independent Chairman of the Board Crinetics Pharmaceuticals Inc Oct. 1, 2015 -
Independent Director Onyx Pharmaceuticals Inc Dec. 1, 1996 -
Independent Director XenoPort Inc Jan. 1, 2000 -
Independent Director Cytokinetics Inc Feb. 9, 2011 -
Independent Director Seelos Therapeutics Inc March 10, 2014 - Jan. 24, 2019
Independent Director Ocera Therapeutics Inc Dec. 19, 2013 - Dec. 11, 2017
Wendall Wierenga's trades of Cytokinetics Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-04-21 2025-04-21
PrS Proposed sale
20,505
47.85
US$573,412 		20,505 47.85 US$573,412
2025-04-21 2025-04-21
S Sale
55,937 +34.1%
118.25
US$803,414 		55,937 +34.1% 118.25 US$803,414
2024-12-16 2024-12-16
PrS Proposed sale
50,653
236.03
US$614,380 		50,653 236.03 US$614,380
2024-12-16 2024-12-16
S Sale
742 -2.9%
48.61
US$36,069 		742 -2.9% 48.61 US$36,069
2024-11-26 2024-11-25
S Sale
742 -2.9%
50.00
US$37,100 		742 -2.9% 50.00 US$37,100
2024-11-25 2024-11-25
PrS Proposed sale
742
50.00
US$37,100 		742 50.00 US$37,100
2024-10-31 2024-10-28
S Sale
4,452 -15.3%
52.25
US$232,617 		4,452 -15.3% 52.25 US$232,617
2024-10-28 2024-10-28
PrS Proposed sale
4,452
52.25
US$232,617 		4,452 52.25 US$232,617
2023-12-27 2023-12-27
PrS Proposed sale
10,000
73.60
US$736,000 		10,000 73.60 US$736,000
2023-12-27 2023-12-27
PlS Planned sale
5,000 -21.1%
73.60
US$368,000 		5,000 -21.1% 73.60 US$368,000
2023-12-27 2023-12-27
PlS Planned sale
5,000 -21.1%
73.60
US$368,000 		5,000 -21.1% 73.60 US$368,000
2023-08-21 2023-08-21
PrS Proposed sale
6,020
32.02
US$192,761 		6,020 32.02 US$192,761
2023-08-21 2023-08-21
S Sale
6,020 -24.9%
32.02
US$192,760 		6,020 -24.9% 32.02 US$192,760
2023-02-08 2023-02-06
PlS Planned sale
7,000 -35.8%
45.00
US$315,000 		7,000 -35.8% 45.00 US$315,000
2022-09-01 2022-09-01
PlS Planned sale
4,166 -25.5%
52.79
US$219,923 		4,166 -25.5% 52.79 US$219,923
2020-04-29 2020-04-28
S Sale
6,666 -100.0%
16.00
US$106,656 		6,666 -100.0% 16.00 US$106,656
2020-04-29 2020-04-28
S Sale
3,333 -100.0%
16.00
US$53,328 		3,333 -100.0% 16.00 US$53,328
2014-10-24 2014-10-22
B Purchase
20,000 +inf%
1.52
US$30,364 		20,000 +inf% 1.52 US$30,364